What is Vivos?
Vivos Therapeutics Inc. is a medical technology firm dedicated to developing and commercializing novel treatments for sleep disordered breathing conditions, with a primary focus on mild to moderate obstructive sleep apnea (OSA). The company's proprietary Vivos System technology is presented as a non-surgical, non-invasive, and non-pharmaceutical alternative to traditional treatments for OSA. By modifying the upper airway's structure and position, the Vivos System aims to enhance airway space, thereby reducing OSA symptoms and improving associated health metrics. The system's efficacy is demonstrated through its ability to significantly lower Apnea Hypopnea Index (AHI) scores. Sales are primarily facilitated through independent dentists participating in the Vivos Integrated Practice (VIP) program, which provides them with training and support.
How much funding has Vivos raised?
Vivos has raised a total of $22M across 2 funding rounds:
Debt
$1M
Stock Offering
$21M
Debt (2020): $1M with participation from PPP
Stock Issuance/Offering (2020): $21M led by Undisclosed
What's next for Vivos?
The substantial enterprise-level funding and recent strategic investment signal a pivotal growth phase for Vivos. This capital infusion is expected to accelerate the company's research and development efforts, expand its market reach, and further commercialize the Vivos System. The focus on non-invasive OSA treatments positions Vivos to capture a significant share of a growing market. Future strategic initiatives will likely involve scaling the VIP program, enhancing clinical validation, and potentially exploring new therapeutic applications for their technology. The company's trajectory suggests a strong emphasis on market penetration and solidifying its innovative treatment modality.
See full Vivos company page
